Skip to main content
SpringerLink
Log in

Do agents that block the RAS truly offer renoprotective effects in early stage, nonproteinuric nephropathy?

  • Published:
Current Hypertension Reports Aims and scope Submit manuscript

Abstract

Clinical practice guidelines from many professional societies endorse renin-angiotensin system (RAS) antagonists as first-line antihypertensive agents in diabetes and chronic kidney disease, largely based on putative renoprotective properties that may be blood pressure (BP) independent. To evaluate the relevance of these recommendations to early stage, nonproteinuric nephropathy, studies of primary and secondary prevention of kidney disease were reviewed. Primary prevention studies were reviewed only for diabetic populations. Secondary prevention studies included hypertensive and normotensive, and diabetic and nondiabetic patients with microalbuminuria or low glomerular filtration rate. Overall, use of RAS antagonists as first-line agents does not appear to be as important as control of BP. To achieve protective levels of BP, multiple antihypertensive agents are usually required. Long-term studies with clinically relevant outcomes (death and loss of kidney function) are needed to clarify whether specific agents provide benefits beyond that of BP control in early stage, nonproteinuric nephropathy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Coresh J, Astor BC, Greene T, et al.: Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003, 41:1–12.

    Article  PubMed  Google Scholar 

  2. Coresh J, Byrd-Holt D, Astor BC, et al.: Chronic kidney disease awareness, prevalence, and trends among US adults, 1999 to 2000. J Am Soc Nephrol 2005, 16:180–188.

    Article  PubMed  Google Scholar 

  3. National Kidney Foundation: K/DOQI clinical practice guidelines on blood pressure management and use of antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004, 43:S1–S290.

    Google Scholar 

  4. Collins AJ, Kasiske B, Herzog C, et al.: Excerpts from the United States Renal Data System 2006 Annual Data Report. Am J Kidney Dis 2007, 49(1 Suppl 1):A6–7, S1–296.

    Article  PubMed  Google Scholar 

  5. Ries LAG, Eisner MP, Kosary CL, et al.: SEER Cancer Statistics Review, 1975–2000. Bethesda, MD: National Cancer Institute. Available at: http://seer.cancer.gov/csr/1975_2000. Accessed April 2007.

    Google Scholar 

  6. Tarnow L, Rossing P, Gall MA, et al.: Prevalence of arterial hypertension in diabetic patients before and after JNC-V. Diabetes Care 1994, 17:1247–1251.

    Article  PubMed  CAS  Google Scholar 

  7. Zatz BR, Dunn R, Meyer WT, et al.: Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 1986, 77:1925–1930.

    PubMed  CAS  Google Scholar 

  8. Anderson S, Meyer WT, Rennke HG, et al.: Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J Clin Invest 1985, 76:612–619.

    Article  PubMed  CAS  Google Scholar 

  9. Long DA, Price KL, Herrera-Acosta J, et al.: How does angiotensin II cause renal injury? Hypertension 2004, 43:722–723.

    Article  PubMed  CAS  Google Scholar 

  10. Cooper ME: Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet 1998, 352:213–219.

    Article  PubMed  CAS  Google Scholar 

  11. Allen TJ, Cao Z, Youssef S, et al.: The role of angiotensin II and bradykinin in experimental diabetic nephropathy: functional and structural studies. Diabetes 1997, 46:1612–1618.

    Article  PubMed  CAS  Google Scholar 

  12. Ravid M, Savin H, Jutrin I, et al.: Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993, 118:577–581.

    PubMed  CAS  Google Scholar 

  13. Lacourière Y, Nadeau A, Poirier L, et al.: Captopril or conventional therapy in hypertensive type II diabetics: three-year analysis. Hypertension 1993, 21:786–794.

    Google Scholar 

  14. Lebovitz HE, Wiegmann TB, Cnaan A, et al.: Renal protective effects of enalapril in hypertensive NIDDM: role of baseline albuminuria. Kidney Int 1994, 45:S150–S155.

    Article  CAS  Google Scholar 

  15. Chobanian AV, Bakris GL, Black HR, et al.: The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003, 289:2560–2572.

    Article  PubMed  CAS  Google Scholar 

  16. Arauz-Pacheco C, Parrott MA, Raskin P, et al.: Treatment of hypertension in adults with diabetes. Diabetes Care 2003, 26:S80–S82.

    Article  PubMed  Google Scholar 

  17. The EUCLID study group: Randomized placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997, 349:1787–1792.

    Article  Google Scholar 

  18. Ravid M, Brosh D, Levi Z, et al.: Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus: a randomized, controlled trial. Ann Intern Med 1998, 128:982–988.

    PubMed  CAS  Google Scholar 

  19. Kvetny J, Gregersen G, Smith Pedersen R, et al.: Randomized placebo-controlled trial of perindopril in normotensive, noromoalbuminuric patients with type 1 diabetes mellitus. Q J Med 2001, 94:89–94.

    CAS  Google Scholar 

  20. Ruggenenti P, Fassi A, Ilieva PA, et al.: Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004, 351:1941–1951.

    Article  PubMed  CAS  Google Scholar 

  21. Estacio RO, Jeffers BF, Gifford N, et al.: Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000, 23:B54–B64.

    PubMed  Google Scholar 

  22. Schrier RW, Estacio RO, Esler A, et al.: Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002, 61:1086–1097.

    Article  PubMed  Google Scholar 

  23. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000, 355:253–259.

    Article  Google Scholar 

  24. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998, 317:703–713.

    Google Scholar 

  25. Strippoli GFM, Craig M, Schena FP, et al.: Antihypertensive agents for primary prevention of diabetic nephropathy. J Am Soc Nephrol 2005, 16:3081–3091.

    Article  PubMed  CAS  Google Scholar 

  26. Griffin KA, Abu-Amarah I, Picken M, et al.: Renoprotection by ACE inhibition or aldosterone blockade is blood pressure-dependent. Hypertension 2003, 41:201–206.

    Article  PubMed  CAS  Google Scholar 

  27. Bidani AK, Griffin KA, Bakris G, et al.: Lack of evidence of blood pressure-independent protection by renin-angiotensin system blockade after renal ablation. Kidney Int 2005, 57:1651–1661.

    Article  Google Scholar 

  28. Lewington S, Clarke R, Qizilbash N: Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data on one million adults in 61 prospective studies. Lancet 2002, 360:1903–1913.

    Article  PubMed  Google Scholar 

  29. Bianchi S, Bigazzi R, Baldari G, et al.: Microalbuminuria in patients with essential hypertension: effects of an angiotensin converting enzyme inhibitor and of a calcium channel blocker. Am J Hypertens 1991, 4:291–296.

    PubMed  CAS  Google Scholar 

  30. Bigazzi R, Bianchi S, Baldari D, et al.: Long-term effects of a converting enzyme inhibitor and a calcium channel blocker on a urinary albumin excretion in a patients with essential hypertension. Am J Hypertens 1993, 6:108–113.

    PubMed  CAS  Google Scholar 

  31. Bianchi S, Bigazzi S, Baldari G. Microalbuminuria in patients with essential hypertension: effects of several hypertensive drugs. Am J Med 1992, 93:525–528.

    Article  PubMed  CAS  Google Scholar 

  32. Aurell M, Bengtsson C, Bjorck S, et al.: Enalapril versus metoprolol in primary hypertension: effects on glomerular filtration rate. Nephrol Dial Transplant 1997, 12:2289–2294.

    Article  PubMed  CAS  Google Scholar 

  33. Marre M, Chatellier G, Leblanc H, et al.: Prevention of diabetic nephropathy with enalapril in normotensive diabetics with microalbuminuria. BMJ 1988, 297:1092–1095.

    Article  PubMed  CAS  Google Scholar 

  34. Trevisan R, Tiengo A: Effect of low-dose ramipril on microalbuminuria in normotensive or mild hypertensive non-insulin dependent diabetic patients. Am J Hypertens 1995, 8:876–883.

    Article  PubMed  CAS  Google Scholar 

  35. Mathiesen ER, Hommel E, Hansen HP, et al.: Randomised controlled trial of long term efficacy of captopril on preservation of kidney function in normotensive patients with insulin dependent diabetes and microalbuminuira. BMJ 1999, 319:24–25.

    PubMed  CAS  Google Scholar 

  36. Parving HH, Lehnert H, Brochner-Mortensen J, et al.: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001, 345:870–878.

    Article  PubMed  CAS  Google Scholar 

  37. Rahman M, Pressel S, Davis BR, et al.: Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2005, 165:936–946.

    Article  PubMed  CAS  Google Scholar 

  38. Casas JP, Chua W, Loukogeorgakis S, et al.: Effect of inhibitors of renin-angiotensin system and other antihypertensive drugs on renal outcomes: systemic review and meta-analysis. Lancet 2005, 366:2026–2033.

    Article  PubMed  CAS  Google Scholar 

  39. Suissa S, Hutchinson T, Brophy JM, et al.: ACE-inhibitor use and the long-term risk of renal failure in diabetes. Kidney Int 2006, 69:913–919.

    Article  PubMed  CAS  Google Scholar 

  40. Baba S, J-Mind Study Group: Nifedipine and enalapril equally reduce the progression of nephropathy in hypertensive type 2 diabetics. Diabetes Res Clin Pract 2001, 54:191–201.

    Article  PubMed  CAS  Google Scholar 

  41. Chan JCN, Ko GTC, Leung DHY, et al.: Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients. Kidney Int 2000, 57:590–600.

    Article  PubMed  CAS  Google Scholar 

  42. Velussi M, Brocco E, Frigato F, et al.: Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients. Diabetes 1996, 45:216–222.

    Article  PubMed  CAS  Google Scholar 

  43. Viberti G, Wheeldon NM for the MicroAlbuminuria Reduction with VALsartan (MARVAL) Study Investigators: Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002, 106:672–678.

    Article  PubMed  CAS  Google Scholar 

  44. Marre M, Puig JG, Kokot F, et al.: Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR study. J Hypertens 2004, 22:1613–1622.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Providence Medical Research Center and Sacred Heart Medical Center, University of Washington School of Medicine, PO Box 2555, 101 West 8th Avenue, Spokane, WA, 99220-2555, USA

    Radica Alicic

Authors
  1. Radica Alicic
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Katherine R. Tuttle
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Radica Alicic.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Alicic, R., Tuttle, K.R. Do agents that block the RAS truly offer renoprotective effects in early stage, nonproteinuric nephropathy?. Current Science Inc 9, 393–402 (2007). https://doi.org/10.1007/s11906-007-0073-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11906-007-0073-8

Keywords

Search

Navigation